In collaboration with
Dissolution Science: Principles and Applications
Over the course of three days, we’ll cover dissolution topics covering a range current topics with industry and academia’ leading experts!
Date and time
Mon, Sep 19, 2022, 9:00 AM –
Wed, Sep 21, 2022, 4:00 PM EDT
Location
Meeting Agenda
Sep 19: Development of quality drug products, Predictive Dissolution to guide formulation development
| Welcome – Session Chair: Patrick Ballmer, Vice President, SOTAX Group | ||
| Time | Title | Speaker |
| 09:00 am – 09:05 am | Introduction | Patrick Ballmer, Board Member, SPDS US Chapter and Vice President, SOTAX Group |
| 09:05 am – 09:10 am | Welcome | Dr. Ramaswamy Lakshmanan, General Secretary, SPDS-India |
| 09:10 am – 09:15 am | Welcome | Dr. Vinod P. Shah, President, SPDS US Chapter |
| 09:15 am – 09:25 am | Welcome | Dr. Tina Morris, CEO, AAPS |
| 09:25 am – 09:40 am | Keynote Address | Dr. Navnit Shah, SVP and Scientific Advisor, Amneal Pharmaceuticals |
| 09:40 am – 09:55 am | Keynote Address | Pankajbhai Patel, Chairman, Zydus Life Sceinces Ltd., India |
| Session I: Development of quality drug products – Session Chair: Samir Haddouchi, Managing Director, SPS Pharma Services | ||
| Time | Title | Speaker |
| 10:00 am – 10:30 am | Evolution of Dissolution in Pharmaceutical Science | Dr. Vinod P Shah, President, SPDS US Chapter |
| 10:30 am – 11:00 am | Coffee break | |
| 11:00 am – 11:30 am | Challenges Dissolution Science is facing in the Brand Name Pharmaceutical Industry | Dr. Xujin Lu, Research Fellow, BMS |
| 11:30 am – 12:00 am | Challenges Dissolution Science is facing in the Generics Industry | Dr. Prasad Panzade, Head, Analytical Operations and Laboratory Platforms. Protagene |
| 12:00 pm – 12:30 pm | Panel Discussion. Questions & Answers. | |
| 12:30 pm – 02:00 pm | Lunch break | |
| Session II: Predictive Dissolution to Guide Formulation Development – Session Chair: Dr. David Sperry, Senior Research Advisor, Eli Lily | ||
| Time | Title | Speaker |
| 02:00 pm – 02:30 pm | Biorelevant dissolution media | Dr. Deanna Mudie, Principal Scientist, Lonza |
| 02:30 pm – 03:00 pm | Linking predictive dissolution data in early development and pre-clinical studies | Dr. Steve Stamatis, Sr. Consultant Engineer, Eli Lily |
| 03:00 pm – 03:30 pm | Coffee Break | |
| 03:30 pm – 04:00 pm | In vitro predictive tools to understand biopharmaceutics risk assessment- Precipitation risk | Sanjay Patel, Principal Scientist, Merck |
| 04:00 pm – 04:30 pm | Prediction of oral drug absorption using a hollow fiber membrane (HFM) module | Dr. James Polli, Professor, University of Maryland |
| 04:30 pm – 05:00 pm | Panel Discussion. Questions & Answers. | |
| 05:00 pm – 06:00 pm | Wine & Cheese | |
Sep 20: Understanding of Dissolution Mechanism to guide robust formulation development, Role of Dissolution in regulatory submission
| Session III: Understanding of Dissolution Mechanism to Guide Robust Formulation Development – Session Chair: Dr. Deanna Mudie, Principal Scientist, Lonza | ||
| Time | Title | Speaker |
| 09:00 am – 09:30 am | Factors influencing dissolution | Dr. Arvind Bansal, Dean, NIPER, India |
| 09:30 am – 10:00 am | Understanding dissolution mechanism | Dr. David Sperry, Senior Research Advisor, Eli Lilly |
| 10:00 am – 10:30 am | Modeling and Simulations (driving towards RTRT) | Dr. Tessa Carducci, Assoc. Principal Scientist, Merck |
| 10:30 pm – 11:00 am | Coffee Break | |
| 11:00 pm – 11:30 pm | Dissolution safe space | Dr. Tyco Heimbach, Principal Scientist, Merck |
| 11:30 pm – 12:00 pm | Use of dissolution testing to support clinical bridging studies | Dr. Vivek Purohit, Sr. Director Clinical Pharmacology, Pfizer |
| 12:00 pm – 12:30 pm | Panel Discussion. Questions & Answers. | |
| 12:30 pm – 02:00 pm | Lunch break | |
| Session IV: Role of Dissolution in Regulatory Submission – Session Chair: Dr. Xujin Lu, Research Fellow, BMS | ||
| Time | Title | Speaker |
| 02:00 pm – 02:30 pm | Dissolution Data Integrity: Who did what, when and where? | Ajay Pydah, Lead Software and Data Management, SOTAX Group |
| 02:30 pm – 03:00 pm | M9 and Beyond | Talia Flannagan, Head of Product Design and Performance, UCB, Belgium |
| 03:00 pm – 03:30 pm | Coffee Break | |
| 03:30 pm – 04:00 pm | Establishing clinically relevant dissolution specifications | Dr. Andre Hermans, Director, Merck |
| 04:00 pm – 04:30 pm | Agency perspective on evaluating dissolution data in product development and in product life cycle | Dr. Mei Ou, Biopharmaceutics Reviewer, FDA |
| 04:30 pm – 05:00 pm | Panel Discussion. Questions & Answers. | |
Sep 21: Dissolution of Special Dosage Forms
| Session V: Dissolution of Special Dosage Forms – Session Chair: Sanjay Patel, Principal Scientist, Merck | ||
| Time | Title | Speaker |
| 09:00 am – 09:30 am | Advanced Third Generation Solid Dispersion Films – Facile Innovative Technology | Dr. Padma Devrajan, Professor, Institute of Chemical Technology, India |
| 09:30 am – 10:00 am | Characterization and Quality Comparison of Liposome Formulations | Dr. Anna Schwendeman, William I. Higuchi Collegiate Professor, University of Michigan |
| 10:00 am – 10:30 am | IV, IVC | Dr. Diane Burgess, Board of Trustees and Distinguished Professor of Pharmaceutics, University of Connecticut |
| 10:30 pm – 11:00 am | Coffee Break | |
| 11:00 pm – 11:30 pm | Biodegadable polymers. | Dr. John Middleton, Vice President of Polymer Development, Tolmar |
| 11:30 pm – 12:00 pm | Global implementation for automated dissolution testing for commercial Release Testing | Dr. Zachery Custer, Sr. Scientist, Merck |
| 12:00 pm – 12:30 pm | Panel Discussion. Questions & Answers. | |
| 12:30 pm – 02:00 pm | Lunch break | |
| 2:00 pm – 04:00 pm | Tour of SOTAX Westborough Facilities | |
Elizabeth Bielski, M.S., Ph.D. is a Senior Pharmacologist working at Division of Therapeutic Performance-I (DTP-I), Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center of Drug Evaluation and Research (CDER) at the FDA since October 2022. Prior to her role as a Senior Pharmacologist, she served as a Pharmacologist (October 2020-October 2022) and as a Chemist (January 2020 t-October 2020) within DTP-I. Her areas of expertise involve orally inhaled and nasal drug products (OINDPs) and drug-device combination products (DDCPs). She is actively involved in developing general and product-specific guidances, addressing controlled correspondences, pre-ANDA meeting requests, citizen petitions, internal consults, and collaborating on current research projects to promote generic drug development of OINDPs and DDCPs. Prior to joining the FDA, she served as an ORISE Fellow at FDA within DTP from August 2018-December 2019. Elizabeth completed her Ph.D. in Chemical Engineering from Wayne State University (Detroit, MI, USA) in July 2018 encompassing work also conducted at Department of Chemistry at the University of São Paulo (São Paulo, Brazil) and Department of Pharmaceutics at Virginia Commonwealth University (Richmond, VA, USA) related to novel inhaled drug delivery strategies for treatment of lung cancer and lung metastases. Prior to receiving her doctorate, she received her Bachelor of Science in Biomedical Physics Honors with University Honors in 2011, and her Master of Science in Biomedical Engineering in 2012 from Wayne State University.
James Mullin is a Senior Principal Scientist at Simulations Plus, Inc. and has a graduate degree in Chemical Engineering. In his role at Simulations Plus, he contributes to modeling and simulation development and consulting activities across multiple programs including GastroPlus, MembranePlus, and DDDPlus. Most recently, James is participating in an FDA grant project to extend the capability of Gastroplus to predict local tissue concentrations by enhancing the model structure. Additionally, he has developed models to predict partitioning in pulmonary tissues and simulate inhalation of vapors for purposes of toxicological modeling and assessments. James has 19 years’ experience in PBPK modeling, computational fluid dynamics, and mathematical modeling.
Dr. Ross Walenga joined the FDA in 2015 as an Oak Ridge Institute for Science and Education (ORISE) Fellow. He is currently a Chemical Engineer at the Division of Quantitative Methods and Modeling at the Office of Research and Standards. He began his career at Virginia Polytechnic Institute and State University (Virginia Tech), where he earned a Bachelor Science in Aerospace Engineering. He later earned his Ph.D. in Engineering (mechanical track) from Virginia Commonwealth University in 2014, where he also spent seven months as a postdoctoral fellow prior to joining the FDA. His research interests include computational fluid dynamics modeling of orally inhaled, nasal, ophthalmic, and dermal drug products to answer questions pertaining to bioequivalence.
Dr. Vaka is a Director of Formulation R & D, specialty product division at Amneal Pharmaceuticals. He obtained his Ph.D in Pharmaceutics & Drug Delivery from the University of Mississippi. After graduating, he worked at Kashiv Pharmaceuticals LLC., for about 8 years in R & D, focusing on 505(b)(2) programs. He developed GRANDE® (advanced gastric retention system) and KRONOTEC® (advanced osmotic oral drug delivery system) proprietary technology platforms for controlled drug delivery of challenging compounds that significantly improve efficacy, tolerability and compliance. He has authored 25+ research articles in peer-reviewed international journals, 2 book chapters and is an inventor on over 15 patents.
Nilay Patel is a Director of Pre-Formulation & Analytical R&D for the Specialty & complex generics product division at Amneal Pharmaceuticals. He holds a Master’s degree in Pharmaceutical Sciences from Stevens Institute of Technology. Nilay joined Amneal in 2010 as a scientist in the Analytical R&D department and has since progressed through a series of leadership positions within the company. Throughout his tenure at Amneal, Nilay has gained extensive experience working with a wide range of dosage forms, including oral, semisolid, ophthalmic, otic, implants, transdermal, nasal, and inhalation formulations. He has played a pivotal role in suggesting in-vitro alternatives to clinical testing for complex generic products. Currently, he is actively involved in supporting 505(b)(2) programs, focusing on establishing in-vitro models for proprietary gastro-retentive oral dosage forms using multiple approaches.
Patrick serves as Vice President and Deputy of the CEO of the Aesch, BL, Switzerland headquartered SOTAX Group. Raised in Switzerland and educated at ETH Zurich, he moved to Pennsylvania in 2005 and Massachusetts in 2009 to develop the presence of SOTAX in the United States. Today he oversees all activities of SOTAX in North- and South America, including Production, Product Development and Application Laboratories at SOTAX in Westborough, MA. A Chemist by training, his research interests prior to joying SOTAX were in the areas of Medicinal and Computational Chemistry.